Amgen Inc. (NASDAQ:AMGN) Position Boosted by Ayrshire Capital Management LLC

Ayrshire Capital Management LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,015 shares of the medical research company’s stock after acquiring an additional 122 shares during the period. Ayrshire Capital Management LLC’s holdings in Amgen were worth $1,047,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Johnson & White Wealth Management LLC boosted its position in shares of Amgen by 106.9% during the 4th quarter. Johnson & White Wealth Management LLC now owns 2,069 shares of the medical research company’s stock valued at $536,000 after purchasing an additional 1,069 shares in the last quarter. Leibman Financial Services Inc. lifted its stake in Amgen by 6.8% during the fourth quarter. Leibman Financial Services Inc. now owns 12,800 shares of the medical research company’s stock valued at $3,336,000 after purchasing an additional 818 shares during the last quarter. Exeter Financial LLC boosted its holdings in Amgen by 2.8% during the fourth quarter. Exeter Financial LLC now owns 11,424 shares of the medical research company’s stock worth $2,978,000 after buying an additional 313 shares in the last quarter. PSI Advisors LLC grew its position in Amgen by 25.1% in the fourth quarter. PSI Advisors LLC now owns 503 shares of the medical research company’s stock worth $131,000 after buying an additional 101 shares during the last quarter. Finally, Granite Bay Wealth Management LLC increased its holdings in shares of Amgen by 6.7% in the fourth quarter. Granite Bay Wealth Management LLC now owns 16,069 shares of the medical research company’s stock valued at $4,188,000 after buying an additional 1,005 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of several research reports. Sanford C. Bernstein assumed coverage on Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price on the stock. Robert W. Baird restated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. UBS Group cut their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Citigroup cut their target price on shares of Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Finally, Jefferies Financial Group restated a “buy” rating and set a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $314.91.

Amgen Stock Up 3.0 %

Shares of NASDAQ:AMGN opened at $270.19 on Tuesday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a market capitalization of $145.24 billion, a PE ratio of 34.60, a P/E/G ratio of 2.91 and a beta of 0.56. The company’s fifty day moving average is $278.16 and its 200-day moving average is $308.35. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the company earned $4.96 EPS. Equities research analysts predict that Amgen Inc. will post 19.53 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 121.90%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.